Related Experiment Video
Updated: Apr 28, 2026

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
Bone marrow transplant for a girl with bone marrow failure and cerebral palsy
Yuichi Kodama1, Yasuhiro Okamoto, Yuichi Shinkoda
1Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Insights
Bone marrow transplantation (BMT) can be safe for children with congenital bone marrow failure syndrome (CBMFs) and severe comorbidities like cerebral palsy (CP). However, neurological benefits from BMT in these complex cases are not guaranteed.
Area of Science:
- Hematology
- Pediatric Medicine
- Neurology
Background:
- Congenital bone marrow failure syndromes (CBMFs) are often treated with bone marrow transplantation (BMT).
- Comorbidities complicate BMT decisions due to potential toxicities.
- This case involves a child with CBMFs, severe cerebral palsy (CP), and mental retardation (MR), requiring transfusions despite medical management.
Observation:
- The patient underwent a successful BMT from an HLA-1 locus-mismatched unrelated donor.
- Engraftment was achieved post-transplantation.
- No neurological improvement was observed five years after the BMT.
Findings:
- Bone marrow transplantation (BMT) is a viable option for patients with congenital bone marrow failure syndromes (CBMFs) even with significant comorbidities such as severe cerebral palsy (CP) and mental retardation (MR).
- Successful engraftment does not necessarily correlate with neurological recovery in these patients.
Implications:
- While BMT can be safely performed in CBMFs patients with CP and MR, the potential for neurological improvement should be carefully considered.
- Further research is needed to understand the long-term neurological outcomes and potential benefits of BMT in pediatric patients with complex comorbidities.
Abstract:
Bone marrow transplantation (BMT) has been used with increasing frequency to treat congenital bone marrow failure syndrome (CBMFs) successfully. Decision to perform BMT, however, is difficult in the case of comorbidity because of regimen-related toxicities. We describe here a child with CBMFs, severe cerebral palsy (CP) at Gross Motor Function Classification System level V and mental retardation (MR) who was transfusion dependent despite various medications. She underwent BMT from an HLA-1 locus-mismatched unrelated donor. Although engraftment was successful, no neurological improvement was seen 5 years after BMT. While CBMFs patients who have CP and MR could undergo transplantation safely, they may not benefit neurologically from BMT.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

